CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
CLINICAL DATA
The ULTIMA Trial
SEATTLE II Trial
OPTALYSE PE
Nykamp-Laurich
Vascular Surgery / Venous Thromboembolism Portal / Pulmonary Embolism / Clinical Data / Nykamp-Laurich

 

Nykamp & Laurich Study
EKOS Endovascular System PE Clinical Studies

 

 

Safety and Efficacy of Ultrasound-Accelerated Catheter-Directed Lytic Therapy in Acute Pulmonary Embolism With and Without Haemodynamic Instability
Nykamp M et al. J Vasc Surg: Venous and Lymphatic Disorders 2015: 3(5) 251-7

Nykamp & Laurich Study

 

Key Results

Acute PE patients treated with EKOS therapy showed:

  • Complete resolution of cardiac dysfunction in 64% of patients immediately post procedure.
  • Direct pulmonary artery pressure showed an average reduction of 40.2%.
  • No deaths through 90 days of follow-up and no major periprocedural bleeding events.
  • Fewer adverse events at 2-year follow-up compared to patients treated with anticoagulation only.
  • Shorter average length of stay: EKOS treated = 3.2 days vs. AC = 6.7 days.

 

Average Length of Stay: EKOS Treated = 3.2 Days vs. AC = 6.7 Days
Average Length of Stay: EKOS Treated = 3.2 Days vs. AC = 6.7 Days


Conclusions

EKOS therapy is an effective PE treatment for reducing pulmonary artery pressures and resolving haemodynamic abnormalities, with excellent mortality and complication rates.

 

 

Top